MedTrace Logo

Cardiovascular Safety Research: Bupivacaine With Vasoconstrictor Versus Ropivacaine in Brachial Plexus Block

NCT00523289 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2009-02-19

No results posted yet for this study

Summary

The purpose of this study is to determine if bupivacaine (75% levobupivacaine plus 25% racemic bupivacaine) with vasoconstrictor is effective and safety as ropivacaine in brachial plexus block for orthopedic surgery.

Conditions

  • Injuries, Hand
  • Anesthesia Conduction
  • Anesthetics, Local

Interventions

DRUG

Bupivacaine

Dosage: 150mg at once for anesthesia induction

DRUG

Ropivacaine

Single dose of ropivacaine, 150mg

Sponsors & Collaborators

  • Cristália Produtos Químicos Farmacêuticos Ltda.

    collaborator INDUSTRY

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • José Otávio C Auler Junior, PhD/Chairman · Hospital das Clínicas - Medicine School of the University of São Paulo

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-03-31
Completion
2009-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00523289 on ClinicalTrials.gov